244 related articles for article (PubMed ID: 35212590)
1. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer.
Lobo N; Martini A; Kamat AM
Expert Rev Anticancer Ther; 2022 Apr; 22(4):361-370. PubMed ID: 35212590
[TBL] [Abstract][Full Text] [Related]
2. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
3. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
4. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue "Seminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma".
Chu C; Pietzak E
Urol Oncol; 2023 Oct; 41(10):398-409. PubMed ID: 35811207
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
Loriot Y; Rouprêt M
Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
[TBL] [Abstract][Full Text] [Related]
7. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z
Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Kokorovic A; Ory J; Saad F
Curr Opin Support Palliat Care; 2022 Mar; 16(1):48-53. PubMed ID: 35086977
[TBL] [Abstract][Full Text] [Related]
9. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R; Kobayashi T; Hidaka Y; Abe H; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Kamiyama M; Morita S; Ogawa O; Nishiyama H; Kitamura H; Sugimoto M;
Urol Oncol; 2022 Mar; 40(3):107.e1-107.e9. PubMed ID: 34454824
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
11. Current advances in BCG-unresponsive non-muscle invasive bladder cancer.
Tse J; Singla N; Ghandour R; Lotan Y; Margulis V
Expert Opin Investig Drugs; 2019 Sep; 28(9):757-770. PubMed ID: 31412742
[No Abstract] [Full Text] [Related]
12. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
Hugar LA; Gilbert SM; Sexton WJ; Kamat AM; Li R
Curr Opin Urol; 2021 Mar; 31(2):160-169. PubMed ID: 33394766
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
17. Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer.
Suh J; Yoo S
Transl Cancer Res; 2020 Oct; 9(10):6537-6545. PubMed ID: 35117263
[TBL] [Abstract][Full Text] [Related]
18. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
19. New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.
Audisio A; Buttigliero C; Delcuratolo MD; Parlagreco E; Audisio M; Ungaro A; Di Stefano RF; Di Prima L; Turco F; Tucci M
Cells; 2022 Jan; 11(3):. PubMed ID: 35159167
[TBL] [Abstract][Full Text] [Related]
20. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
